Our regular round-up of financings in the biotech sector features rounds for TORL BioTherapeutics, Nvelop Therapeutics, D3 Bio, and Century Therapeutics. Antibody-drug conjugate specialist TORL has ...
LOS ANGELES, June 9, 2025 /PRNewswire/ -- TORL BioTherapeutics LLC (TORL), a clinical-stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend ...
Proceeds Fund the Clinical Development of TORL-1-23, Currently in a Registrational Phase 2 Study for Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer and in Phase 1 for other CLDN6+ ...
$158M Series B-2 Financing led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management, Perceptive Advisors, and Avidity Partners as ...
Co-founded by acclaimed oncologist Dennis Slamon, M.D., Ph.D., of University of California at Los Angeles (UCLA) and entrepreneur and CEO David Licata, as well as leadership from a distinguished set ...
LOS ANGELES, Sept. 10, 2024 /PRNewswire/ -- TORL BioTherapeutics, LLC (TORL), a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend ...
Torl Biotherapeutics LLC has raised $158 million in a series B round as it seeks to nudge its anti-Claudin-6 antibody-drug conjugate candidates, TORL-123 and TORL-2307, beyond phase I trials for the ...
LOS ANGELES, April 13, 2023 /PRNewswire/ -- TORL BioTherapeutics LLC (TORL), a biopharmaceutical company focused on developing new biologics for cancer treatment, announced today its public launch and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results